The Bear Room, page-193

Going off all the new posters today, I'd suggest that the low is in and the stop loss hunters have filled their desired positions.

SP is a gift at the moment. I suspect the bow will be tied and cu6 will be sold for $20-$30/share within 6-12 months. The average premium paid by BP is 100% to last closing price, however for more sort after assets this can be as high as 200%. I.e. if the SP is $8, we could expect to wake up one morning with an offer of $24 ($5B USD market cap).

Before the down rampers lose their mind over a $5B USD acquisition price..

"GlobalData analyst consensus forecast predicts the global revenue of Pluvicto to rise from $980 million in 2023 to $4.3 billion by 2030"

https://www.globaldata.com/media/pharma/radiopharmaceuticals-prostate-cancer-go-nuclear-6-3-billion-sales-2030-forecasts-globaldata/#:~:text=17%20Sep%2C%202024%20Radiopharmaceuticals%20for,sales%20by%202030%2C%20forecasts%20GlobalData&text=Radioligand%20therapies%20(RLTs)%20have%20received,companies%20in%20treating%20prostate%20cancer.

Remember Alan is a former investment banker with a significant holding so there's no doubt in my mind that he'll be able to negotiate a great outcome for shareholders.